Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates
Zura Bio Limited - Class A Ordinary shares (ZURA)
Company Research
Source: Business Wire
Achieved key milestones in 2024 that enhanced our leadership team, strengthened our financial position, and progressed our clinical pipelineInitiated the Phase 2 TibuSURE trial in adults with systemic sclerosis (SSc)Completed a $112.5 million private placement financing in April 2024, contributing to a total of $176.5 million in cash and cash equivalents, as of December 31, 2024Cash runway anticipated through 2027, supporting operations and funding anticipated tibulizumab data readouts in SSc and hidradenitis suppurativa (HS) HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflamma
Read more
Impact Snapshot
Event Time:
ZURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZURA alerts
High impacting Zura Bio Limited - Class A Ordinary shares news events
Weekly update
A roundup of the hottest topics
ZURA
News
- Zura Bio Limited (NASDAQ: ZURA) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc..MarketBeat
- Zura Bio Limited (NASDAQ: ZURA) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $15.00 price target on the stock.MarketBeat
- Zura Bio Limited (NASDAQ: ZURA) had its price target lowered by analysts at Chardan Capital from $12.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
- Zura Bio to Present at the Leerink Partners Global Healthcare ConferenceBusiness Wire
ZURA
Earnings
- 11/7/24 - Miss
ZURA
Sec Filings
- 3/25/25 - Form 8-K
- 3/25/25 - Form 10-K
- 3/25/25 - Form 8-K
- ZURA's page on the SEC website